
CANF Stock Forecast & Price Target
CANF Analyst Ratings
Bulls say
Can-Fite Biofarma Ltd is a clinical-stage biopharmaceutical company focusing on developing therapeutics targeting cancer, liver diseases, and inflammatory conditions, with promising candidates in pivotal clinical trials. The company anticipates significant revenue growth, projecting risk-adjusted sales from Can-Fite products to rise from approximately $3 million in 2027 to around $126 million by 2031, with Namodenoson alone expected to contribute approximately $19.7 million in global sales by that year. Furthermore, the strong clinical results, including a complete response in a patient treated with Namodenoson, along with FDA and EMA agreement on the Phase 3 protocol for Piclidenoson, enhance the company's outlook and strengthen its market position.
Bears say
The financial outlook for Can Fite Biofarma Ltd is negatively impacted by several fundamental concerns, particularly regarding its product commercialization and regulatory approval processes. The company has projected a net loss of $10 million for 2025, continuing a trend indicated by a $4.9 million loss in the first half of 2025, which raises concerns about its financial health and ability to sustain operations without additional funding. Furthermore, anticipated dilution from adjustments in the stock model, along with competitive pressures and potential intellectual property challenges, could significantly hinder Can Fite's revenue generation and market penetration, leading to a downward revision of its future valuation.
This aggregate rating is based on analysts' research of Can-Fite BioPharma Ltd. and is not a guaranteed prediction by Public.com or investment advice.
CANF Analyst Forecast & Price Prediction
Start investing in CANF
Order type
Buy in
Order amount
Est. shares
0 shares